Compare Globalstar (GSAT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globalstar vs Smith & Nephew plc — how do they compare? Globalstar trades at $81.98 (market cap $10.60B), while Smith & Nephew plc trades at $27.99 (market cap $11.72B). The key difference: Globalstar and Smith & Nephew plc are close in size by market cap, and Smith & Nephew plc pays a 2.83% dividend while Globalstar pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globalstar for 6 Days and Smith & Nephew plc for 117 Days on average.
| GSAT | SNN | |
|---|---|---|
Market Cap | $10.60B | $11.72B |
Volume | 507,891 | 1,612,340 |
Sector | Media | Health |
52-Week High | $84.43 | $37.39 |
52-Week Low | $32.09 | $27.50 |
Typical Hold Time | 6 Days | 117 Days |
Enterprise Value | $10.60B | $14.75B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSAT trades at $81.83, down 0.79% today, with a bullish technical signal from moving averages despite recent earnings misses. The company reported negative net income margins of -18.49% and elevated valuation ratios (P/S 37.36, EV/EBITDA 117.08). Recent satellite launches aim to strengthen Globalstar's LEO network, while cash flow remains positive with $56.31M net cash flow in 2025.
Investment outlook is mixed: technical momentum supports near-term upside, but fundamental weaknesses in profitability and high valuations pose risks. Analyst consensus shows 40% buy ratings with no sell recommendations, suggesting cautious optimism amid execution challenges in satellite network expansion.
Smith & Nephew (SNN) trades at $28.065, up 2.05% today but near 52-week lows following recent analyst downgrades. The stock shows bearish technical signals with neutral oscillators, while fundamentals reveal steady revenue growth to $6.16B in 2025 and improving net margins to 10.08%. Recent news includes a CFO departure and reduced revenue guidance, though the company maintains innovation through new surgical products and partnerships.
The outlook remains cautious with analyst consensus at Hold (65% of ratings) amid execution concerns. Investment opportunities include strong cash flow generation and medical technology innovation, while risks involve U.S. orthopedics weakness, competitive pressures, and leadership transitions. The stock's current valuation at 19.32 P/E offers reasonable entry but requires monitoring of guidance execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Globalstar
Globalstar provides satellite and terrestrial connectivity services, including voice, data, asset tracking, and private wireless solutions. It operates a low-Earth-orbit satellite network and holds licensed mid-band spectrum.
Read more on GSAT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
